Modified Virus Shows Promise in Shrinking Tumors and Halting Cancer Growth
/in Not PCa related/by MaxCRISPR Gene Editing Silences Cancer-Causing Mutations
/in CRISPR, Not PCa related, Preclinical Research/by MaxMistery Solved: How Diabetes Drug Metformin Lowers Blood Sugar by Targeting Cell’s Powerhouse
/in Not PCa related/by MaxA New Hope for Hard-to-Treat Cancers: a New TACC3 Inhibitor
/in Clinical Trial, Not PCa related/by MaxMapping the Gut: A New Atlas Illuminates the Path to Understanding and Treating Cancer (and other diseases)
/in Not PCa related, Preclinical Research/by MaxAI designed cancer drug gets FDA approval for clinical trials
/in Artificial Intelligence, Not PCa related/by MaxThe Future of Cancer Treatment (pan-cancer): A 3-in-1 Antibody Design
/in Immunotherapy, Not PCa related, Preclinical Research/by MaxAnother Potential Breakthrough: 3-in-1 Antibody Shows Promise
/in Immunotherapy, Not PCa related, Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Newsletter 11/2026 March 15, 2026
- Blood Lipid Profiles in Metastatic Prostate Cancer: A Window into Tumor Metabolism and Response to Enzalutamide March 14, 2026
- Organoids from Routine TUR‑P Samples: A Personalized Platform for Prostate Cancer Therapy Testing March 13, 2026
- Estrogen‑Based Androgen Suppression Plus ARSI in Prostate Cancer: A Phase 2 Quality‑of‑Life Trial March 13, 2026